ACXP News and Press, Acurx Pharmaceuticals Inc. From 08/16/21

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2021 Results and Provides Business Update Successful June 2021 IPO Raising $17.25 million in Gross Proceeds Including Exercise of Overallotment Option PR Newswire STATEN ISLAND, N.Y. , Aug. 16, 2021 /PRNewswi...

Acurx Pharmaceuticals Joins the Antimicrobials Working Group PR Newswire WASHINGTON , Aug. 5, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (Acurx) to its coalition of c...

Health Holland Awards Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals -Health Holland has awarded a grant of approximately $500,000 USD to Leiden University Medical Center to further study the mechanism of actio...

Acurx Pharmaceuticals to Discuss 2021 Second Quarter Financial Results on August 17, 2021 Conference Call and Provide Business Update Successful June 2021 IPO Raising $17.25 million in Gross Proceeds Including Exercise of Overallotment Option PR Newswire STATEN ISL...

Acurx Announces Filing of Provisional Patent Application for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving the Health of the Gut Microbiome PR Newswire STATEN ISLAND, N.Y., July 7, 2021 /PRNewswire/ -- Acurx Pharmaceuticals,...

Alterity Therapeutics Limited (ATHE) +57% on a new patent by USPTO.Birks Group (BGI) +49% on re-opening of its retail stores across Canada.Wunong Net Technology Company (WNW) +46%.Spero Therapeutics (SPRO) +23% on $40M equity investment from Pfizer.Bridgeline Digital (BLIN) +21...

Acurx Announces New Ibezapolstat Data on Anti-Recurrence Mechanisms in CDI at Prominent International Conference - Ibezapolstat, the first of a novel class of antibiotics, DNA polymerase IIIC inhibitors, is currently commencing a Phase 2b clinical trial in patients with CDI ...

Antibiotics focused Acurx Pharmaceuticals ([[ACXP]] +0.3%) has completed its $15M IPO, which also included a full exercise by the underwriters to purchase an additional 375K shares at $6 per share.The company says net proceeds after expenses is $14.8M.Alexander Capital was lead book-runner wi...

ACURX PHARMACEUTICALS, Inc. Announces Closing of INITIAL Public Offering OF common stock AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES PR Newswire STATEN ISLAND, N.Y. , June 29, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: A...

Gainers: Intellia Therapeutics (NTLA) +39%, Verve Therapeutics (VERV) +29%, Graybug Vision (GRAY) +24%, Anavex Life Sciences (AVXL) +15%, ReShape Lifesciences (RSLS) +13%.Losers: CEL-SCI (CVM) -38%, Acurx Pharmaceuticals (ACXP) -22%, Exelixis ...